Advancis Pharmaceutical News
Most Popular Advancis Pharmaceutical Story
ALSO NOTED: Elan, Biogen submit Tysabri for Crohn's; Affymax prices IPO;and much more...
> Shares of Elan and Biogen Idec were on the rise this morning after the two developers announced that they had submitted Tysabri as a therapy for Crohn's disease. Report
> Affymax priced its IPO of 3.7 million shares at $25 a share. Release
> Advancis Pharmaceutical …
Read more...Latest Headlines
- October 24, 2006
- September 12, 2006
- August 10, 2006
- February 7, 2006
- September 14, 2005
- July 28, 2005
- July 21, 2005
- June 15, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
